Does the gap in obesity rates fully explain the difference in life expectancy? Or are there other factors at play?
I don't think it actually does, because UK has lower obesity rates than Australia (26-29% versus 32%), yet also lower life expectancy (Australia is 81.1 male, 85.1 female; UK is 78.8 male, 82.8 female)
It also doesn’t seem to vary that much by state level healthcare differences. States vary quite a bit by geography, but states that didn’t do Medicaid expansion, like Wisconsin and Wyoming, seem to have similar rates to neighboring states that did.
The obesity rate in the US is 40%. The just-overweight rate is 33%. So unless we really ramp up on tackling obesity, the life expectancy is going be dragged down.
SubQ pen injections are something even most people afraid of needles can get used to quite quickly, so even if the pill forms never get to the same efficacy there's really no reason that they couldn't solve it for most everyone once they go generic and become affordable, or become otherwise subsidized. China already produces the APIs in huge quantities for insanely cheap for sale on the black market, so we know that they can be produced for extremely low costs.
The tragedy of short term thinking.
This is the even more effective pill that is about to hit the market:
https://www.lilly.com/news/stories/what-to-know-about-orforg...
>11. How much will orforglipron cost?
>LLilly recently announced an agreement with the U.S. government to expand access to its obesity medicines and reduce patient costs. Upon FDA approval, self-pay patients living with obesity will be able to access orforglipron through LillyDirect's self-pay pharmacy channel with the lowest dose starting at $149 with additional doses up to $399.
Maybe it should be free but it's quite affordable at 50, that is relatively easy to make up in saved junk-food/snack costs.